

## CONTENTS

NOTE TO THE READER .....	5
LIST OF PARTICIPANTS .....	7
PREAMBLE	
Background .....	11
Objective and Scope .....	11
Selection of Topics for Monographs .....	12
Data for Monographs .....	13
The Working Group .....	13
Working Procedures .....	14
Exposure Data .....	14
Biological Data Relevant to the Evaluation of Carcinogenicity to Humans .....	16
Evidence for Carcinogenicity in Experimental Animals .....	17
Other Relevant Data in Experimental Systems and in Humans .....	19
Evidence for Carcinogenicity in Humans .....	21
Summary of Data Reported .....	24
Evaluation .....	25
References .....	29
GENERAL REMARKS .....	33
THE MONOGRAPHS	
<b>Antineoplastic and immunosuppressive agents</b>	
Azacitidine .....	47
Chlorozotocin .....	65
Ciclosporin .....	77
Prednimustine .....	115
Thiotepa .....	123
Trichlormethine (Trimustine hydrochloride) .....	143

## CONTENTS

### Antimicrobial agents

Ampicillin .....	153
Chloramphenicol .....	169
Nitrofurantoin (Nitrofurazone) .....	195
Nitrofurantoin .....	211

### Other drugs

Cimetidine .....	235
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) .....	265
Furosemide (Frusemide) .....	277
Hydrochlorothiazide .....	293
Paracetamol (Acetaminophen) .....	307

SUMMARY OF FINAL EVALUATIONS .....	333
------------------------------------	-----

APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS .....	335
--	-----

APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS .....	337
---	-----

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-49 .....	385
--	-----

CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES .....	387
--	-----